Let me start by saying your protocol and the results are ground-breaking and fascinating. I'm thankful that you're documenting it so well and sharing it with everyone.
You've explored the impact of enclomiphene on your protocol by discontinuing it, with some confounding by simultaneous dose adjustment and lower serum testosterone. Have you done the same with gonadorelin? I would suggest the combination of dosing as low as yours combined with enclomiphene might result in some measurable HPTA activity without the gonadorelin.
I'm also curious about the impact of enclomiphene on your symptoms. It is widely reported that enclomiphene therapy produces eugonadal lab values in just about everyone with secondary hypogonadism. However, symptom resolution is often partial or nonexistent. When these same individuals progress to full-blown TRT, even with the same lab values, they usually report better results. The common explanation for this phenomenon is that it occurs due to blocking of estrogen receptors, whose activation is essential to fully realize the benefits of TRT. Everyone here knows testosterone doesn't do much besides muscle anabolism on its own -- it's basically a pro-drug for DHT and E2 in most tissues.
In other words, potentially half the benefit of TRT could be jeopardized by enclomiphene's ER antagonism. I'm curious whether you've noticed any negative impact from it. You would be an unusual example if there were truly none.
